Passage Bio, Inc. (PASG) Tops Q2 EPS by 5c

Passage Bio, Inc. (NASDAQ: PASG) reported Q2 EPS of ($0.26), $0.05 better than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Passage Bio, Inc. (PASG) click here.

You May Also Be Interested In

• Trex (TREX) Reiterated at Hold by Benchmark as Partnership Agreement Announced
• First Hawaiian (FHB) Reiterated at Hold by Benchmark as Chico Acquisition Announced
• Fastenal (FAST) Reports In-Line Q2 EPS, Beats on Revenue